PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-1.07
Negative OCF/share while CRVO has 0.00. Joel Greenblatt would question the viability of operations in comparison.
-1.08
Negative FCF/share while CRVO stands at 0.00. Joel Greenblatt would demand structural changes or cost cuts.
-0.04%
Both companies show negative capex-to-OCF ratios. Martin Whitman would see if the sector is unprofitable or if accounting anomalies exist.
0.61
Positive ratio while CRVO is negative. John Neff would note a major advantage in real cash generation.
No Data
No Data available this quarter, please select a different quarter.